Reske Sven N, Blumstein Norbert M, Glatting Gerhard
Klinik für Nuklearmedizin, Universität Ulm, Robert-Koch-Strasse 8, 89081, Ulm, Germany.
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):9-17. doi: 10.1007/s00259-007-0530-2. Epub 2007 Sep 9.
The aim of this study was to assess the accuracy and clinical impact of [(11)C]choline PET/CT for localizing occult relapse of prostate adenocarcinoma after radical prostatectomy.
Fourty-nine patients with prostate adenocarcinoma, radical prostatectomy, no evidence of metastatic disease, and occult relapse underwent [(11)C]choline PET/CT. Thirty-six of the patients had biochemical evidence and histological evaluation of local recurrence. Thirteen patients had PSA < 0.3 ng/ml and no evidence of active disease after 1 year follow-up. Focal nodular [(11)C]choline uptake in the prostatic fossa was visually assessed and graded on a five point scale. Maximum standardized radioactivity uptake value (SUV(max)) and the lesion size were measured. A receiver operating characteristic (ROC) analysis was performed and the clinical impact of the PET/CT study was determined.
[(11)C]choline PET/CT was true positive in 23/33 patients and true negative in 12/13 controls. SUV(max) of local recurrence was 3.0 (median, range 0.6-7.4) and 1.1 (0.4-1.6) in controls (p = 0.0002). Lesion size was 1.7 cm (range 0.9-3.7). Area under the ROC curve for detecting relapse was 0.90 +/- 0.05 and 0.83 +/- 0.06 for visual evaluation and SUV(max), respectively. Sensitivity and specificity of [(11)C]choline PET/CT were 0.73 and 0.88, respectively. [(11)C]choline PET/CT identified 12/17 (71%) patients with a favourable biochemical response to local radiotherapy at 2 year (median, 0.8-3.2 range) follow-up.
Focally increased [(11)C]choline uptake in the prostatic bed reliably predicted local low volume occult relapsing prostate adenocarcinoma after radical prostatectomy and identified 71% of patients with a favourable biochemical response to local radiotherapy.
本研究旨在评估[(11)C]胆碱PET/CT在定位前列腺癌根治术后隐匿性复发方面的准确性及临床影响。
49例前列腺癌患者,接受了前列腺癌根治术,无转移疾病证据且存在隐匿性复发,接受了[(11)C]胆碱PET/CT检查。其中36例患者有生化证据及局部复发的组织学评估。13例患者前列腺特异抗原(PSA)<0.3 ng/ml,且在1年随访后无疾病活动证据。对前列腺窝内局灶性结节状[(11)C]胆碱摄取进行视觉评估并按五分制分级。测量最大标准化摄取值(SUV(max))及病变大小。进行了受试者操作特征(ROC)分析,并确定了PET/CT检查的临床影响。
[(11)C]胆碱PET/CT在23/33例患者中为真阳性,在12/13例对照中为真阴性。局部复发的SUV(max)为3.0(中位数,范围0.6 - 7.4),对照中为1.1(0.4 - 1.6)(p = 0.0002)。病变大小为1.7 cm(范围0.9 - 3.7)。检测复发的ROC曲线下面积,视觉评估为0.90±0.05,SUV(max)为0.83±0.06。[(11)C]胆碱PET/CT的敏感性和特异性分别为0.73和0.88。[(11)C]胆碱PET/CT在2年(中位数,范围0.8 - 3.2)随访时,识别出12/17(71%)例对局部放疗有良好生化反应的患者。
前列腺床内[(11)C]胆碱摄取局部增加可可靠地预测前列腺癌根治术后局部小体积隐匿性复发病例,并识别出71%对局部放疗有良好生化反应的患者。